Published responses

All responses were provided to the HTA Review Reference Committee for its consideration shortly after they were received. An analysis of the responses received through Consultation 1 is currently being prepared. Submissions received  will be published unless it was requested that they not be published at the time of making the submission. 

If you have any questions, please email the HTA Review Secretariat at htareviewconsult@health.gov.au.

Search responses

114 Published responses

Response 3601263
Jaffe
Canteen
Lymphoma Australia
ausEE Inc.
Genetic Support Network of Victoria
Telix Pharmaceuticals
THEMA Consulting
Response 772675517
zalcberg
National Paediatric Medicines Forum
Response 756091278
Australian Pathology
Musculoskeletal Australia
Response 705623916
UCB
Pharmaceutical Research and Manufacturers of America (PhRMA)
Eczema Support Australia
Prince
Camurus Australia
Cancer Health Services Research (Centre for Health Policy, University of Melbourne)
Roche
Arthritis Australia
Health Economics and Health Services Research Group, Flinders University
Research Australia
HTANALYSTS
South Australian Department for Health and Wellbeing
Public Pathology Australia
PRIMCAT Consumer Panel (Independent Panel Chair - University of Melbourne)
Response 563531843
Ovarian Cancer Australia
AstraZeneca
Australian Genomics
Council of Australian Therapeutic Advisory Groups
Illumina
The Australasian College of Dermatologists
DEBRA Australia
Painaustralia
Dementia Australia
Response 452232897
Response 480816214
Alexion AstraZeneca Rare Disease
Vertex Pharmaceuticals
Response 381139850
Response 478800307
Neurological Alliance Australia
ANDHealth
Novartis Pharmaceuticals Australia Pty Ltd
Response 201429565
Response 739213965
Melanoma Patients Australia
Pathology Technology Australia
Myasthenia Alliance Australia (MAA)
AbbVie
Australian Patients Association
Medicines Australia
Amgen
Rare Cancers Australia
Breast Cancer Network Australia
AUSTRALIAN PATIENT ADVOCACY ALLIANCE LTD
Page 1 of 2